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Fenretinide stimulates redox-sensitive ceramide production in
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The synthetic retinoid N-(4-hydroxphenyl) retinamide (4HPR) has manifold actions, which may contribute to its chemopreventive
effects on breast cancer cell growth and progression. A role for ceramide as a stress-response signal is investigated here during the
cytotoxic action of 4HPR in MCF-7 cells. N-(4-hydroxphenyl) retinamide induced a dose-dependent decline in cell growth and
survival associated with a maximal 10-fold increase in ceramide production at 10mM. N-(4-hydroxphenyl) retinamide exhibited a
greater potency than all-trans retinoic acid (ATRA) on growth inhibition and ceramide production. The synthetic peroxisome
proliferator-activated receptors agonist troglitazone (TGZ), but not the native ligand 15-deoxy-delta 12,14-prostaglandin J2,
abrogated both these actions of 4HPR but not that of ATRA. The antioxidant N-acetylcysteine mimicked the abrogative effect of
TGZ on 4HPR action, while the exogenous oxidant H2O2 also stimulated ceramide production. The inhibitors of de novo ceramide
synthesis, fumonisin B1 and myriocin, blocked the ceramide response to 4HPR and partially reversed the apoptotic response, but did
not prevent the overall decline in cell survival. The pancaspase inhibitor Z-VAD fmk reduced the decrease in cell survival caused by
4HPR, but did not affect the ceramide response. These findings describe a novel redox-sensitive elevation of ceramide levels
associated with the cytotoxic response of breast cancer cells to 4HPR. However, a major mediatory role for this sphingolipid in this
context remains equivocal.
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The potential application of retinoids for breast cancer prevention
and treatment reflects their important role as regulators of cell
growth and differentiation. Retinoids initiate many of their actions
by ligand-induced dimerisation of retinoic acid receptors (RARs)
and retinoid X receptors, followed by receptor binding to retinoid
response elements on DNA and transactivation of retinoid-
response target genes. All-trans retinoic acid (ATRA), the most
potent naturally occurring metabolite of vitamin A, reversibly
inhibits the growth of hormone-dependent human breast cancer
cells, requiring the activation of RARa-mediated gene transcrip-
tion for this effect (Dawson et al, 1995). Synthetic modification of
the carboxyl end of retinoic acid with an N-4 hydroxyphenyl group
results in the formation of N-4-(hydroxyphenyl) retinamide
(4HPR) or fenretinide. N-4-(hydroxyphenyl) retinamide is more
potent than ATRA, both as an antiproliferative agent and inducer
of apoptosis in the majority of cancer cell lines tested (Oridate et al,
1996; Zou et al, 1998). Compared with ATRA, 4HPR exhibits
reduced hepatotoxicity and increased efficacy in inhibiting
mammary carcinogenesis in animal models (Ulukaya and Wood,
1999). Recent clinical studies also highlight a potential chemopre-
ventative action of 4HPR on breast cancer recurrence in high-risk
premenopausal women (Veronesi et al, 1999; Decensi et al, 2000).
Although 4HPR can transactivate certain retinoid receptors and
RAR antagonists can partially block 4HPR-induced apoptosis (Sun
et al, 1999) compared with ATRA, 4HPR binds with low affinity to
RAR and demonstrates poor transactivation of RAR/RXR response
elements in human breast cancer cells (Sheikh et al, 1995).
Retinoid receptors can also interact with peroxisome proliferator-
activated receptors (PPARs) either directly through the formation
of heterodimers (Schulman et al, 1998) or indirectly by regulating
their mutual expression (Stoll, 2002; James et al, 2003). In this
regard, when combined with PPARg agonists such as troglitazone
(TGZ), ATRA synergistically and irreversibly inhibits growth and
induces apoptosis in human breast cancer cells (Elstner et al,
1998). Whether PPARg agonists manifest similar interactions with
4HPR in breast cancer cells is unknown.
As well as activating receptor-mediated mechanisms, retinoids
such as 4HPR may modulate cell function via alternative receptor-
independent pathways involving cellular signals such as reactive
oxygen species (ROS) (Sun et al, 1999) and the sphingolipid
ceramide (DiPietrantonio et al, 1998).
Evidence supporting a role for ceramide during 4HPR action on
HL-60 leukaemia cells and neuroblastoma cells is based on studies
demonstrating an elevation of cellular ceramide levels in response
to 4HPR and the ability of the ceramide synthase inhibitor
fumonisin B1 (FB1) to block this ceramide response and prevent
4HPR-induced apoptosis (DiPietrantonio et al, 1998; Maurer et al,
1999). However, in other instances where induction of apoptosis is
accompanied by an elevation of ceramide, FB1 failed to prevent the
apoptotic response while blocking ceramide production (Nagy
et al, 2000; Miguet et al, 2001).
Several studies have also demonstrated a role for ROS during the
induction of apoptosis by 4HPR in various cell types (Sun et al,
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y1999; Suzuki et al, 1999). Furthermore, cellular redox status and
ROS are also known to regulate critical steps in a wide variety of
cellular functions including sphingolipid pathways involved in
stress-response signalling (Andrieu-Abadie et al, 2001). The nature
and relevance of ceramide production and signalling, and its
relationship to redox status during 4HPR action in human breast
cancer cells, are unknown.
A better understanding of the molecular mechanisms involved
in the cytotoxic actions of anticancer agents such as 4HPR is
crucial for the further development and chemotherapeutic use of
such drugs. In the present study with the human breast cancer cell
line MCF-7, we have compared the effects and interactions of both
native and synthetic retinoids (ATRA and 4HPR) and PPARg
agonists (15-deoxy-delta 12,14-prostaglandin J2, 15d-PGJ2 and
TGZ) on cell growth, survival and ceramide production. Under a
variety of conditions, retinoid action on cell growth, survival and
cytotoxicity was associated with corresponding changes in
ceramide production. N-(4-hydroxphenyl) retinamide exhibited
much greater potency and efficacy than ATRA on inhibiting cell
growth and inducing ceramide production and cytotoxicity.
Troglitazone, but not 15d-PGJ2, blocked the antiproliferative and
cytotoxic actions of 4HPR and reduced the ceramide response,
possibly as a consequence of its antioxidant properties. Although
FB1 prevented the ceramide response to 4HPR, the decline in cell
survival was unaffected.
MATERIALS AND METHODS
Materials
Unless otherwise stated, all sphingolipid standard chemicals,
reagents and materials for cell culture were purchased from Sigma
(Poole, Dorset, UK). Culture media and supplements were
obtained from ICN Biochemicals (High Wycombe, UK). 15-deoxy-
delta 12,14-prostaglandin J2 was obtained from Affiniti Research
Products (Exeter, UK), TGZ was a gift from Glaxo Wellcome
(Uxbridge, UK) and SDZ PSC 833 was a gift from Novartis Pharma
AG (Basel, Switzerland).
Cell culture
MCF-7 cells were obtained from the European Collection of
Animal Cell Cultures (Salisbury, UK) and maintained at 371Ci n
Eagle’s minimal essential medium (EMEM) supplemented with
glutamine (2mM), nonessential amino acids and 10% foetal calf
serum. For all experiments monitoring cell growth, apoptosis and
ceramide production cell stocks grown in 25cm
2 flasks were
trypsinised and seeded into six-well plates in supplemented EMEM
containing penicillin (100Uml
 1), streptomycin (100mgml
 1) and
amphotericin-b (250ngml
 1).
Cell growth
The effects of various treatments (see legends for details) on MCF-
7 cell growth were monitored over a 72h period. Trypsinised cells
were seeded into six-well plates and allowed to plate down for 18h
prior to addition of treatments. Cell numbers were determined at
the end of the growth period by counting isolated cell nuclei by the
Coulter principle following treatment of intact cells with Zaponin
(Coulter, Luton, UK).
Cell survival
The effects of various treatments on MCF-7 cell survival was
monitored after a 72h incubation period using the Promega MTS
assay (Madison, WI, USA) as an index of cell viability. The
tetrazolium compound MTS is bioreduced by cells into a coloured
formazan product that absorbs light at 490nm. Absorbance is
proportional to the number of viable cells present. Trypsinised
cells were diluted to a concentration of 10
5cellsml
 1 and 50ml
aliquots were seeded into 96-well plates (5000cellswell
 1). After a
6h plating period, various treatments were added in 50ml and the
cells incubated for a further 72h in EMEM containing supple-
ments. After this incubation, 20ml of MTS assay reagent was added
and absorbance measured at 490nm after 90min of colour
development. After subtracting the background absorbance of
cell-free incubations, cell survival was determined by expressing all
values as a percentage of control absorbance measured in the
absence of treatment.
DNA fragmentation ELISA
This photometric enzyme-immunoassay measures cytoplasmic
histone-associated DNA fragments (mono- and oligonucleo-
somes), which are generated during apoptosis (Roche Applied
Science). The enrichment of nucleosomes in the cytoplasm of
treated cells is expressed as a fold induction of apoptosis compared to
untreated controls. Assay samples were prepared according to the
manufacturer’s instructions (Roche Applied Science, Mannheim,
Germany). MCF-7 cells were seeded in supplemented EMEM into
96-well plates at 10
4cellswell
 1. After 18h, treatments were added
(see legend Figure 6 for details) and the cells incubated for a
further 24h. The medium was then removed and cell lysates were
prepared and centrifuged for 10min at 200g. A measure of 20ml
aliquots of the supernatant (cytoplasmic fraction) was then
assayed for nucleosome content by ELISA in accordance with the
manufacturer’s protocol.
Sphingolipid metabolism
Ceramide and glucosylceramide were measured by radiolabelled
incorporation of [
3H] palmitic acid into the appropriate sphingo-
lipids, as described previously (Cabot et al, 1998). MCF-7 cells
were grown to approximately 70% confluence in six-well plates in
2ml of supplemented EMEM. At this point, the fresh medium was
added containing the various treatments (see legends for details)
and [
3H]palmitic acid (1mCiml
 1) (Amersham, UK). The cells
were then incubated for a further 24h. Experiments were
terminated by the removal of the medium and addition of 2ml
acidified methanol (2% acetic acid). Any non-adherent cells were
retrieved by centrifugation. Cellular lipids were allowed to be
extracted into the methanol over a 30min period at room
temperature. This methanol extract was removed to glass tubes
and the lipids extracted into a chloroform phase following addition
and mixing with 2ml chloroform and 2ml of KCl/EDTA (2 M/
5m M). Total cellular radiolabelled lipid was measured by counting
a 100ml aliquot of this chloroform extract following solvent
evaporation. The ceramide standard containing primarily stearic
and nervonic species (C18 and C24) was added to a 1ml aliquot of
each lipid extract sample to act both a carrier and marker. These
ceramide species were separated from the remaining lipids by TLC
in the solvent system chloroform/acetic acid (90:10,vv
 1). C18 and
C24 ceramide were also resolved from one another in this system
with Rf values of 0.29 and 0.38, respectively. However, this system
does not resolve the biologically inactive dihydroceramides.
Glucosylceramide was resolved from other lipids by TLC in the
solvent system chloroform/methanol/ammonia (70:20:4, vv
 1)
also using appropriate commercial standards, as described above.
Resolved lipid bands were visualised by staining with iodine
vapour, scraped into scintillation vials containing 0.5ml water and
10ml ECOSCINT, and radioactivity measured by liquid scintilla-
tion counting. The majority of [
3H]palmitic acid incorporated into
cellular lipids was present as phospholipid esters. These polar
lipids remained at the origin in the solvent systems used and in no
instances where changes in ceramide production were observed in
response to 4HPR, were there significant accompanying changes in
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ytotal phospholipid. Similarly, no significant changes in total
cellular lipids were observed in response to any experimental
treatments. Values for radiolabelled incorporation into ceramide
and glucosylceramide are expressed as a percentage of total
cellular lipid. Such ‘normalisation’ of the data will compensate for
any skewness in the data, which would occur if any treatments also
affected general permissive lipid pathways such as fatty acid
uptake or CoA ester formation. Similarly, elongation, desaturation
or recycling may occur in certain [
3H]palmitate pools in response
to treatments, which could slightly skew the results obtained only
if the resulting palmitate metabolites are selectively or preferen-
tially incorporated by ceramide-producing pathways.
Temporal changes in sphingomyelin levels and ceramide
production were also monitored in MCF-7 cells prelabelled to
steady-state levels with [
3H]palmitic acid (1mCiml
 1) for 24h.
Sphingomyelin was resolved from total cellular lipids by TLC in
the solvent system chloroform/methanol/acetic acid/water
(50:30:7:4, vv
 1).
Expression of data and statistical analysis
Unless otherwise stated, all values are presented as the mean7s.d.
from individual representative experiments each carried out in
triplicate on two or more occasions. Statistical significance of
differences between experimental groups was determined by
analysis of variance followed by unpaired Student’s t-test.
RESULTS
Differential action of 4HPR, ATRA and PPARc agonists
on cell growth morphology and survival
The RAR agonist ATRA (5mM) reduced MCF-7 cell growth by
around 50% after 72h, whereas 4HPR (5mM) prevented any net cell
growth during this period (Figure 1A). The synthetic PPARg
agonist TGZ blocked this action of 4HPR but had no effect on
ATRA-induced growth inhibition (Figure 1A). In contrast, the
putative PPARg agonist 15d-PGJ2 had no effect on 4HPR action
(Figure 1B), suggesting that the interaction of TGZ and 4HPR
may be PPARg-independent. N-(4-hydroxphenyl) retinamide
also induced a ‘cytotoxic morphology’ with increased cell round-
ing, vacuolation and detachment, and this action was also blocked
by TGZ (Figure 2). Neither ATRA nor TGZ alone had any
significant effect on cell morphology (unpublished observations).
Since ROS have been implicated during 4HPR-induced cytotoxicity
and TGZ may possess free radical scavenging properties due to
its a-tocopherol moiety, the effects of the antioxidants
a-tocopherol and N-acetylcysteine on 4HPR action were also
investigated. Both a-tocopherol (10mM) and N-acetylcysteine
(10mM) partially reversed the inhibitory action of 4HPR on cell
growth by 3473 and 4575%, respectively (Po0.01, n¼3) in
addition to reducing the 4HPR-induced cytotoxic morphology
(unpublished observations).
N-(4-hydroxphenyl) retinamide stimulates redox-sensitive
ceramide production
The dose-dependent decrease in cell survival after 72h in response
to 4HPR was mirrored by a preceding increase in ceramide
production after 24h (Figure 3A). Consistent with previous
studies, 4HPR also induced an apparent 266% increase in
apoptosis as measured by the enrichment of cytosolic nucleosomes
after 24h (see Figure 6). Sphingomyelin hydrolysis has been
identified as a mechanism responsible for agonist-induced
ceramide production in a number of studies. In MCF-7 cells
prelabelled to steady-state levels with [
3H]palmitate, no significant
changes in sphingomyelin levels were detected in response to
4HPR over a 24h incubation and no major early changes in
ceramide production were detected before 24h (Figure 3B). In
contrast to the 3.7-fold increase in cellular ceramide levels
observed in response to 4HPR (5mM), ATRA (5mM) elicited a
relatively modest 40% increase in ceramide (Figure 4A).
As seen with the effects of 4HPR on cell growth and morphology,
TGZ also reduced the ceramide response to 4HPR (Figure 4B) as
did the antioxidant N-acetylcysteine (Figure 4B). The addition of
exogenous oxidant in the form of H2O2 mimicked the stimulatory
effect of 4HPR on ceramide production and similarly, N-acetyl-
cysteine also reduced this ceramide response (Figure 4B).
Effect of putative ceramide modulators on 4HPR action
To further investigate a potential mediatory role for ceramide
during 4HPR action, we determined the effects of ceramide
synthase activators and inhibitors and glucosylceramide synthase
inhibition. The amide-linked fatty acid constituents of mammalian
ceramides have acyl chains of varying lengths from 16–24 carbon
atoms (C16–C24). The physiological significance of these different
ceramide species in terms of metabolic function or origin is
unknown. The putative ‘activator’ of de novo ceramide synthesis,
PSC 833, stimulated the incorporation of [
3H]palmitate into both
C18 and C24 ceramide species to similar levels (Table 1). In
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Figure 1 Effect of retinoids and PPARg agonists on breast cancer cell
growth. MCF-7 cells were grown over a 3-day period: (A) in the presence
or absence of 4HPR, 5mM; TGZ, 5mM; or ATRA, 5mM or (B) in the
presence or absence of 4HPR; TGZ, 5mM; or 15d-PGJ2), 5mM. Cell nuclei
were harvested and counted as described (see Materials and Methods).
(A)* Po0.02 for inhibition vs control; **Po0.02 for reversal of 4HPR-
induced growth inhibition by TGZ. (B)* Po0.01 for inhibition vs control
values in the absence of 4HPR; **Po0.02 for reversal of 4HPR-induced
inhibition by TGZ.
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ycontrast, 4HPR caused a much greater (3.3-fold) accumulation of
C24 vs C18 ceramide, an action which was associated with a more
potent cytotoxic response to 4HPR (Table 1). These differential
actions of 4HPR and PSC 833 are not in keeping with a common
mechanism of enhanced ceramide accumulation in response to
these agents. Indeed, such differential effects on ceramide
molecular species may also reflect a differential action of 4HPR
and PSC 833 on palmitate metabolism. The observed effect of PSC
833 in MCF-7 cells is consistent with previous studies (Cabot et al,
1998) and lends further support for a mediatory role for
endogenous ceramide in the control of cell death.
Recent studies have reported an increased ability of drug-
resistant cells to scavenge ceramide via enhanced glycosylation,
thereby minimising ceramide-induced apoptotic death (Lavie et al,
1996; Nicholson et al, 1999). Hence, manipulation of this pathway
may modulate chemotoxicity in cancer cells. The effect of the
glucosylceramide synthase inhibitor (D,-L,-threo)-1-phenyl-2-de-
canoylamino-3-morpholino-1-propanol (PDMP) on 4HPR action
is shown in Table 2. (D,-L,-threo)-1-phenyl-2-decanoylamino-3-
morpholino-1-propanol clearly enhanced the 4HPR-induced de-
cline in cell survival, in addition to reducing glucosylceramide
levels by nearly 70% (Table 2). However, the degree of 4HPR-
induced ceramide accumulation remained unaltered in the
presence of PDMP (Table 2). Furthermore, in contrast to the
three-fold increase in ceramide in response to 4HPR, basal
glucosylceramide levels remained unaffected by the retinoid
(Table 2).
The ceramide synthase inhibitor FB1 reduced the 4HPR-induced
ceramide response by around 90% (Figure 5A). In contrast, the
decline in cell survival after 3 days in the presence of 4HPR was
unaffected by FB1 (Figure 5B). Similarly, FB1 did not prevent the
4HPR-induced cytotoxic morphology (unpublished observations).
Although FB1 alone did not affect the overall cell survival in
control cells after 3 days (Figure 5B), the incorporation of
[
3H]palmitate into ceramide was reduced by around 67%
(Figure 5A), and apoptosis was increased two-fold after 24h
(Figure 6). In relation to respective control values, the apoptotic
response to 4HPR (266%) was reduced to 131% in the presence of
FB1 (Figure 6). Similarly, inhibition of serine palmitoyl transferase,
the initial rate-limiting step in ceramide synthesis, by myriocin,
which inhibited ceramide synthesis by more than 90% (unpub-
lished observations), also reduced the apparent apoptotic response
to 4HPR in addition to inducing apoptosis in the absence of 4HPR
(Figure 6). The pancaspase inhibitor Z-VAD fmk partially reversed
(by approximately 70%) the decline in cell survival due to 4HPR
(Figure 5B), but had no effect on the ceramide response to 4HPR
(Figure 5A). In addition to supporting a role for caspases during
4HPR-induced cell death, these observations indicate that
ceramide production in response to 4HPR is upstream or
independent of caspase activation.
Figure 2 Effect of 4HPR and TGZ on MCF-7 cell morphology. Cells were grown over a 3-day period in the presence or absence of 4HPR, 5mM and/or
TGZ, 5mM:( A) control;(B) 4HPR 5mM;( C) TGZ; (D) 4HPR and TGZ. Note cell rounding and detachment along with cytoplasmic vacuolation in the
presence of 4HPR (B). TGZ blocked this 4HPR-induced cytotoxic morphology (D).
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Figure 3 Effect of 4HPR on sphingolipid metabolism and cell survival. (A)
Cells were grown over a 3-day period in the presence or absence of 4HPR.
Cell survival at the end of this time was assessed by the MTS assay as an
index of cell viability (see Materials and Methods). Total ceramide production
was measured after 24h as determined by the incorporation of [
3H]palmitic
acid into both ceramide species (C18 and C24). Radiolabelled ceramide is
expressed as a percentage of total
3H-labelled cellular lipid, which remained
unchanged in response to 4HPR (see Materials and Methods). (B)
Sphingomyelin levels (open symbols) and ceramide production (closed
symbols) were monitored over a 24h period in the presence (triangles) or
absence (circles) of 4HPR (10mM) in cells previously prelabelled to steady-
state levels with [
3H]palmitate (see Methods and Materials). *Po0.05;
**Po0.01 for significant changes in the presence of 4HPR.
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Figure 4 Effect of ATRA, 4HPR and redox modulators on ceramide
production. MCF-7 cells were grown to approximately 70% confluence and
ceramide production was measured (see Materials and Methods) during a
subsequent 24h period: (A) in the absence or presence of ATRA (2, 5mM)
or 4HPR (2, 5mM); (B) in the absence or presence of 5mM 4HPR, 0.5mM
H2O2,1 0 m M N-acetylcysteine (NAC) or 5mM TGZ. Total ceramide
production is expressed as a percentage of control values determined in
the absence of 4HPR. Control ceramide levels were calculated to be
0.5370.04% of total
3H-labelled lipid. (A)* Po0.02 for stimulation; (B)
*Po0.02 for stimulation; **Po0.05 for reduction of this stimulation.
Table 1 Effect of 4HPR and PSC 833 on ceramide composition and
survival in MCF-7 cells
Ceramide composition % of total lipid
Treatment C18 C24
Cell survival %
of control
Control 0.2170.02 0.1270.02 10075
4HPR 0.5370.05* 1.7770.20* 1872*
PSC 833 0.8270.11* 0.8170.02* 2973*
4HPR¼N-(4-hydroxphenyl) retinamide. Ceramide production was measured after
24h incubation of MCF-7 cells in medium containing [
3H]palmitic acid in the absence
or presence of 4HPR (10mM) or PSC 833 (10mM). Incorporation of radiolabelled
precursor into the ceramide species C18 and C24 was determined following lipid
extraction and TLC. No significant changes in total cellular
3H-labelled lipid were
observed in response to any of the treatments, the respective values for control,
4HPR and PSC 833 being 4483572004, 4081672092 and
4668472995c.p.m.incubation
 1. Cell survival was measured in separate incubations
as described (see Materials and Methods). *Po0.01 for significance vs control values.
Table 2 Effect of 4HPR and PDMP on sphingolipid metabolism and
survival in MCF-7 cells
Sphingolipid levels % of total lipid
Treatment Ceramide Glucosylceramide
Cell survival %
of control
Control 0.4570.04 1.4270.09 10073
4HPR 1.4570.43* 1.3670.07 6972*
PDMP 0.5270.04 0.4670.07* 9075*
4HPR+PDMP 1.4170.22* 0.4470.01* 2772*
4HPR¼N-(4-hydroxphenyl) retinamide. PDMP¼(D,-L,-threo)-1-phenyl-2-decanoy-
lamino-3-morpholino-1-propanol. Incorporation of [
3H]palmitic acid into cellular
ceramide and glucosylceramide was measured following incubation of MCF-7 cells in
the presence or absence of 4HPR (5mM), PDMP (20mM) and 4HPR+PDMP as
described (see Materials and Methods). No significant changes in total cellular
3H-
labelled lipid were observed in response to any of the treatments. Cell survival was
measured in separate incubations as described (see Materials and Methods).
*Po0.02 for significance vs control values.
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The efficacy of 4-HPR as a chemopreventive agent in premeno-
pausal breast cancer is exemplified by a recent phase III clinical
trial, which indicates a reduction both in local recurrence and
incidence of contralateral disease in response to treatment
(Veronesi et al, 1999; Decensi et al, 2000). Elucidating the
molecular mechanisms involved in this action will be important
for the future development and improvement of therapies
employing this retinoid in breast cancer treatment.
In agreement with previous studies (Sheikh et al, 1995), 4-HPR
exhibited a more potent antiproliferative response compared with
the native retinoid ATRA, consistent with an additional role for
receptor-independent pathways in the action of this synthetic
retinoid. In combination with PPARg agonists, retinoids have been
reported to enhance growth inhibition and cell death in human
breast cancer cell lines in vitro (Elstner et al, 1998), possibly via
interactive heterodimerisation of retinoid receptors and PPARg.I n
contrast, we have observed no such synergism on growth
inhibition of MCF-7 cells between ATRA and the synthetic PPARg
agonist TGZ. Indeed, on the contrary, the antiproliferative action
of 4-HPR and induction of a cytotoxic morphology were both
completely blocked in the presence of TGZ. Furthermore, the
putative native PPARg ligand 15d-PGJ2 did not mimic the
abrogative action of TGZ, again suggesting a role for receptor-
independent interactive mechanisms during the combined actions
of 4-HPR and TGZ. This is further supported by the antagonism of
4-HPR-induced growth inhibition and cytotoxicity by the anti-
oxidants a-tocopherol and N-acetylcysteine. Given that TGZ also
possesses antioxidant properties by virtue of its constituent
a-tocopherol moiety, a regulatory function for cellular redox
status can be invoked during 4-HPR action in MCF-7 cells in
the present study.
N-(4-hydroxphenyl) retinamide induced a dose-dependent
decline in cell survival, which was associated with a corresponding
reciprocal dose-related increase in ceramide accumulation. Cer-
amide production in response to 4-HPR was an order of
magnitude greater than that observed in the presence of ATRA,
again consistent with a possible receptor-independent regulation
of ceramide in response to 4-HPR. One potential mediatory
mechanism for this action could be via the modulation of cellular
redox status and/or generation of ROS, since the antioxidant
N-acetylcysteine and the radical scavenger TGZ both reduced this
ceramide response to 4-HPR. In addition, the exogenous oxidant
H2O2 mimicked the stimulatory action of 4-HPR on ceramide
production. Although neutral sphingomyelinase has been pre-
viously proposed as a downstream target of oxidative stress
(Andrieu-Abadie et al, 2001), we found no evidence of a role for
sphingomyelin hydrolysis as a metabolic source for ceramide
during 4-HPR action. Indeed, inhibition of this response to 4-HPR
by FB1 and myriocin indicates a stimulatory action on the de novo
synthesis pathways of ceramide production as the mechanism
mediating this increase in ceramide levels.
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Figure 5 Effects of FB1 and caspase inhibition on 4HPR action. MCF-7
cells were grown over a 3-day period in the absence (open bars) or
presence (hatched bars) of 4HPR (5mM), and in the absence or presence of
FB1 (25mM) or Z-VAD fmK (50mM). (A) ceramide production was
measured after 24h by incorporation of [
3H]palmitic acid (see Materials
and Methods). (B) cell survival was measured after 72h by the MTS assay
(see Materials and Methods). *Po0.01 for significant changes vs control
values measured in the absence of 4HPR; **Po0.02 for significant changes
vs control values measured in the presence of 4HPR.
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Figure 6 Effects of 4HPR, FB1 and myriocin on apoptosis in MCF-7 cells.
Cells were pretreated for 1h with or without FB1 (25mM), myriocin (10mM)
or dimethylsulphoxide vehicle (0.5%), and then incubated for a further 24h
in the presence (hatched bar) or absence (open bars) of 4HPR (5mM).
Apoptosis was determined by ELISA of cytoplasmic DNA–histone
complexes and expressed as fold enrichment of nucleosomes compared
with untreated controls (see Materials and Methods). Percentage values
represent the relative increase in 4HPR-induced apoptosis in the absence
or presence of FB1 or myriocin. *Po0.02 for significant changes vs control
values.
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HPR by FB1, the 4-HPR-induced decline in cell survival after 72h
was not prevented. Although there is thus an apparent dissociation
of a mediatory role for ceramide during this action of 4-HPR, a
dilemma often pertains when employing pharmacological manip-
ulation of sphingolipid metabolism to investigate a functional role
for ceramide. As essential structural and functional membrane
components in growing cells, there is a continual dynamic
turnover of sphingolipids as well as an ongoing requirement for
their de novo synthesis. Compromising these pathways with
enzyme inhibitors such as FB1 and myriocin may also lead to
adverse cytotoxicity and apoptosis (Nakamura et al, 1996; Schmelz
et al, 1998). Indeed, both agents induced apoptosis in MCF-7 cells
in the present study while paradoxically appearing to reduce the
apoptotic response to 4-HPR. Furthermore, inhibition of ceramide
synthase by FB1 may lead to the accumulation of sphinganine, and
other sphingoid bases, which in turn could cause inhibition of cell
growth and induction of apoptosis (Schmelz et al, 1998).
The metabolic fate of endogenous ceramide production may also
be subjected to pharmacological modulation. Enhanced glycosyla-
tion of ceramide by glucosylceramide synthase may contribute to
multidrug resistance in cancer cells by abrogation of ceramide-
mediated cell death signalling (Lavie et al, 1996). In this respect,
transformed cells exhibit a synergistic increase in cytotoxicity in
response to 4-HPR in the presence of glucosylceramide synthase
inhibitors (Nicholson et al, 1999). In the present study such an
inhibitor, PDMP, did indeed enhance the decline in cell survival in
response to 4-HPR. However, such findings must be interpreted
with caution, since while inhibiting basal glycosylceramide
production, PDMP did not modify the 4-HPR-induced ceramide
response. Furthermore, it has been recently reported that PDMP
also inhibits nucleoside transport independent of ceramide
production (Griner and Bollag, 2000). It thus remains equivocal
as to whether glucosylceramide synthase plays a major role in
modulating a putative drug-sensitive ceramide pool during 4-HPR
action in MCF-7 cells. Indeed, the 4-HPR-sensitive ceramide pool
appeared not to be in short-term metabolic equilibrium with that
of glucosylceramide, since levels of the latter sphingolipid
remained unchanged in response to 4-HPR. In contrast, under
the same conditions, stimulation of de novo ceramide production
in MCF-7 cells by PSC 833 led to increases in both ceramide and
glycosylceramide (Cabot et al, 1998).
We have employed PSC 833, which stimulates the rate-limiting
step, serine palmitoyltransferase (Wang et al, 2002), ostensibly as a
positive control in the activation of de novo ceramide production.
A differential mechanism of action for the stimulation of de novo
ceramide synthesis by PSC 833 and 4-HPR in the present study was
also evident in the qualitative and quantitative nature of the
ceramide species produced; the major species produced being C18
or C24 in response to PSC 833 or 4-HPR, respectively. The
functional significance of these differences in relation to an active
role for ceramide during drug-induced cytotoxicity is unknown.
However, it is interesting to note that an increased accumulation of
C24 ceramide was associated with a more potent loss of cell
survival in response to 4-HPR vs PSC 833.
Mechanistic differences in cell signalling in response to 4-HPR
and PSC 833 also include opposing actions on cellular redox.
Several studies have reported the elevation of ROS in response to
4-HPR in various cell types (Sun et al, 1999) and in this context, we
have already proposed a mediatory role for oxidative stress during
4-HPR action on ceramide production and cell survival in the
present study; on the other hand, PSC 833 has been reported to
suppress the generation of ROS (Nguyen et al, 1998). A role for
ceramide has been recently implicated during nitric oxide-induced
cell death (Rabkin, 2002) and 4-HPR is known to induce nitric
oxide synthase in breast cancer cells (Simeone et al, 2002).
However, in a preliminary study employing different nitric oxide
synthase inhibitors, we found no evidence of a mediatory role for
nitric oxide during 4-HPR-induced ceramide production in breast
cancer cells (Abbara and Schrey, 2003).
The relationship of caspase activation and ceramide production
with respect to 4-HPR action is unclear. Caspase-3 may partially
mediate 4-HPR-induced apoptosis in some cell types (Perry, 2000)
and ceramide can activate caspase-3 (Mizushima et al, 1996); a
potential mediatory role for ceramide can thus be hypothesised
during drug-induced caspase activation. However, since MCF-7
cells express a mutant nonfunctional caspase-3 due to a 47 base
pair deletion in exon 3 of the CASP-3 gene (Janicke et al, 1998),
such a role is unlikely in the present instance. Furthermore, in the
case of caspase-3-dependent apoptosis induction by daunorubicin
in lymphoblastic leukaemia cells, ceramide synthase appears to be
a downstream target of caspase action (Turnbull et al, 1999). In the
present study, the effect of the pancaspase inhibitor Z-VAD fmk
suggests that at least 70% of the decline in MCF-7 cell survival in
response to 4-HPR is caspase-dependent. On the other hand,
ceramide production in response to 4-HPR was unaffected by
Z-VAD fmk, indicating it to be either upstream or independent of
caspase activation.
Consistent with findings described above on 4-HPR action in
MCF-7 cells, in the case of MDA MB 231 breast cancer cells we have
recently observed a similar paradoxical differential action of both FB1
and myriocin on overall cell survival vs apoptosis. Thus, the decline in
cell survival in response to 4-HPR after 72h is unaffected by blockade
of ceramide production, whereas apoptosis monitored after 24h is
partially prevented (Abbara and Schrey, 2003). Such observations
illustrate the complex manifold actions of 4-HPR, which may cause
cell death by mixed apoptosis/necrosis by both caspase-dependent
and -independent pathways (DiPietrantonio et al, 1998; Maurer et al,
1999). Indeed, in contrast to the caspase-dependent nature of 4-HPR
action on MCF-7 survival described in the present study, caspase
activation was not required for 4-HPR-induced cytotoxicity in MDA
MB 231 cells (unpublished observations).
The present study describes a novel redox-sensitive stimulation
of ceramide production in breast cancer cells by 4-HPR. Although
elevation of this sphingolipid is associated with the cytotoxic
action of 4-HPR, a major mediatory role for ceramide in this
context remains equivocal. Our findings also highlight a need for
caution when interpreting a functional role for ceramide signalling
during 4-HPR action, when it is based on the effects of putative
modulators of ceramide metabolism.
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